New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:41 EDTINCYIncyte says FDA accepts sNDA for Jafaki
Incyte Corporation announced that the U.S. FDA has accepted for filing the supplemental New Drug Application for ruxolitinib as a potential treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. The sNDA includes results from the RESPONSE Phase III trial, which were recently presented at the 2014 American Society of Clinical Oncology annual meeting. RESPONSE was conducted under a Special Protocol Assessment from the FDA. The Prescription Drug User Fee Act date for the sNDA for ruxolitinib is set for December 5, 2014.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
07:15 EDTINCYIncyte lowers FY15 Jakafi revenue view to $525M-$565M from $560M-$575M
Lowers FY15 R&D expenses view to $450M-$500M from $475M-$500M. Lowers FY15 selling, general, and administrative expenses view to $180M-$200M from $195M-$210M.
07:12 EDTINCYIncyte reports Q2 EPS 5c, consensus (11c)
Subscribe for More Information
August 3, 2015
08:55 EDTINCYIncyte price target raised to $125 from $115 at Leerink
Leerink raised its price target for Incyte to $125 saying its survey of 49 U.S. hematologists indicated Jakafi has blockbuster potential in polycythemia vera. The firm keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use